<?xml version='1.0' encoding='utf-8'?>
<document id="2590838"><sentence text="Effect of amantadine on motility of reserpinized mice as a function of brain biogenic amines and mouse strains."><entity charOffset="10-20" id="DDI-PubMed.2590838.s1.e0" text="amantadine" /></sentence><sentence text="The effect of amantadine, reserpine or both on locomotor activity and whole brain content of selected biogenic amines and major metabolites was studied as a function of mouse strain"><entity charOffset="14-24" id="DDI-PubMed.2590838.s2.e0" text="amantadine" /><entity charOffset="26-35" id="DDI-PubMed.2590838.s2.e1" text="reserpine" /><pair ddi="false" e1="DDI-PubMed.2590838.s2.e0" e2="DDI-PubMed.2590838.s2.e0" /><pair ddi="false" e1="DDI-PubMed.2590838.s2.e0" e2="DDI-PubMed.2590838.s2.e1" /></sentence><sentence text=" Successive administration of small dose regimens of reserpine, 0"><entity charOffset="53-62" id="DDI-PubMed.2590838.s3.e0" text="reserpine" /></sentence><sentence text="2 mg/kg IP, did not alter motility from corresponding saline control" /><sentence text=" Administration of amantadine, 100 mg/kg, IP, prior to each of the reserpine treatments produced either stimulation of motor activity in the albino ICR and black C57BL/6 mice or caused inhibition from reserpine in the albino BALB/C and the brown CDF-1 mouse strains"><entity charOffset="19-29" id="DDI-PubMed.2590838.s5.e0" text="amantadine" /></sentence><sentence text=" This suggests a genotype strain sensitivity to the amantadine and reserpine interaction on the motor behavior of the mouse"><entity charOffset="52-62" id="DDI-PubMed.2590838.s6.e0" text="amantadine" /><entity charOffset="67-76" id="DDI-PubMed.2590838.s6.e1" text="reserpine" /><pair ddi="false" e1="DDI-PubMed.2590838.s6.e0" e2="DDI-PubMed.2590838.s6.e0" /><pair ddi="false" e1="DDI-PubMed.2590838.s6.e0" e2="DDI-PubMed.2590838.s6.e1" /></sentence><sentence text=" The amantadine treatment did not alter brain dopamine concentration but increased its immediate acid metabolite, 3,4-dihydroxyphenylacetic acid, in the C57BL/6 mice as contrasted with reduction of the same in the BALB/C mouse strain"><entity charOffset="5-15" id="DDI-PubMed.2590838.s7.e0" text="amantadine" /><entity charOffset="46-54" id="DDI-PubMed.2590838.s7.e1" text="dopamine" /><entity charOffset="114-144" id="DDI-PubMed.2590838.s7.e2" text="3,4-dihydroxyphenylacetic acid" /><pair ddi="false" e1="DDI-PubMed.2590838.s7.e0" e2="DDI-PubMed.2590838.s7.e0" /><pair ddi="false" e1="DDI-PubMed.2590838.s7.e0" e2="DDI-PubMed.2590838.s7.e1" /><pair ddi="false" e1="DDI-PubMed.2590838.s7.e0" e2="DDI-PubMed.2590838.s7.e2" /><pair ddi="false" e1="DDI-PubMed.2590838.s7.e1" e2="DDI-PubMed.2590838.s7.e1" /><pair ddi="false" e1="DDI-PubMed.2590838.s7.e1" e2="DDI-PubMed.2590838.s7.e2" /></sentence><sentence text=" Both BALB/C and C57BL/6 mice showed changes in brain normetanephrine levels as a consequence of the pharmacologic intervention used which suggest catecholaminergic sensitivity"><entity charOffset="54-69" id="DDI-PubMed.2590838.s8.e0" text="normetanephrine" /></sentence><sentence text=" The only changes produced by the agents studied in brain serotonin or 5-hydroxyindoleacetic acid levels were confined to the BALB/C mouse strain"><entity charOffset="58-67" id="DDI-PubMed.2590838.s9.e0" text="serotonin" /><entity charOffset="71-97" id="DDI-PubMed.2590838.s9.e1" text="5-hydroxyindoleacetic acid" /><pair ddi="false" e1="DDI-PubMed.2590838.s9.e0" e2="DDI-PubMed.2590838.s9.e0" /><pair ddi="false" e1="DDI-PubMed.2590838.s9.e0" e2="DDI-PubMed.2590838.s9.e1" /></sentence><sentence text=" No changes occurred in brain levels of the compounds measured from corresponding controls in the CDF-1 mice" /><sentence text=" The results indicate differential sensitivity of the serotonergic and dopaminergic systems to drug-drug interaction studied which appears to be strain dependent" /><sentence text="" /></document>